A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study is a non-randomized, open, multiple administration and dose escalation phase 1
clinical trial evaluating the safety, tolerability, and pharmacokinetic/pharmacodynamics
Characteristics of multiple oral administration of LPM3480226 in patients with advanced solid
tumors., determine its dose-limiting toxicity and maximum tolerated dose, and initially
observe its clinical effectiveness, and explore the metabolites in plasma after
administration.
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Collaborators:
Nan Jing KangHai Lin Zhi Biotechnology Co., Ltd. Nanjing Bangnuo Biotechnology Co. Ltd